TY - JOUR
T1 - Parathyroid hormone resistance syndromes – Inactivating PTH/PTHrP signaling disorders (iPPSDs)
AU - Elli, Francesca Marta
AU - Pereda, Arrate
AU - Linglart, Agnès
AU - Perez de Nanclares, Guiomar
AU - Mantovani, Giovanna
PY - 2018
Y1 - 2018
N2 - Metabolic disorders caused by impairments of the Gsα/cAMP/PKA pathway affecting the signaling of PTH/PTHrP lead to features caused by non-responsiveness of target organs, in turn leading to manifestations similar to the deficiency of the hormone itself. Pseudohypoparathyroidism (PHP) and related disorders derive from a defect of the α subunit of the stimulatory G protein (Gsα) or of downstream effectors of the same pathway, such as the PKA regulatory subunit 1A and the phosphodiesterase type 4D. The increasing knowledge on these diseases made the actual classification of PHP outdated as it does not include related conditions such as acrodysostosis (ACRDYS) or progressive osseous heteroplasia (POH), so that a new nomenclature and classification has been recently proposed grouping these disorders under the term “inactivating PTH/PTHrP signaling disorder” (iPPSD). This review will focus on the pathophysiology, clinical and molecular aspects of these rare, heterogeneous but closely related diseases.
AB - Metabolic disorders caused by impairments of the Gsα/cAMP/PKA pathway affecting the signaling of PTH/PTHrP lead to features caused by non-responsiveness of target organs, in turn leading to manifestations similar to the deficiency of the hormone itself. Pseudohypoparathyroidism (PHP) and related disorders derive from a defect of the α subunit of the stimulatory G protein (Gsα) or of downstream effectors of the same pathway, such as the PKA regulatory subunit 1A and the phosphodiesterase type 4D. The increasing knowledge on these diseases made the actual classification of PHP outdated as it does not include related conditions such as acrodysostosis (ACRDYS) or progressive osseous heteroplasia (POH), so that a new nomenclature and classification has been recently proposed grouping these disorders under the term “inactivating PTH/PTHrP signaling disorder” (iPPSD). This review will focus on the pathophysiology, clinical and molecular aspects of these rare, heterogeneous but closely related diseases.
KW - GNAS
KW - inactivating PTH/PTHrP signaling disorders (iPPSD)
KW - PDE3A
KW - PDE4D
KW - PRKAR1A
KW - pseudohypoparathyroidism (PHP)
UR - http://www.scopus.com/inward/record.url?scp=85054583409&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054583409&partnerID=8YFLogxK
U2 - 10.1016/j.beem.2018.09.008
DO - 10.1016/j.beem.2018.09.008
M3 - Article
AN - SCOPUS:85054583409
SN - 1521-690X
VL - 32
SP - 941
EP - 954
JO - Best Practice and Research in Clinical Endocrinology and Metabolism
JF - Best Practice and Research in Clinical Endocrinology and Metabolism
IS - 6
ER -